Contineum Therapeutics (CTNM) Competitors $3.98 -0.03 (-0.63%) Closing price 02:42 PM EasternExtended Trading$4.07 +0.10 (+2.42%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. TYRA, MAZE, VALN, SEPN, ATYR, MREO, CGEM, AMLX, ZYBT, and ORKAShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Tyra Biosciences (TYRA), Maze Therapeutics (MAZE), Valneva (VALN), Septerna (SEPN), aTyr Pharma (ATYR), Mereo BioPharma Group (MREO), Cullinan Therapeutics (CGEM), Amylyx Pharmaceuticals (AMLX), Zhengye Biotechnology (ZYBT), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Tyra Biosciences Maze Therapeutics Valneva Septerna aTyr Pharma Mereo BioPharma Group Cullinan Therapeutics Amylyx Pharmaceuticals Zhengye Biotechnology Oruka Therapeutics Contineum Therapeutics (NASDAQ:CTNM) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Which has more risk and volatility, CTNM or TYRA? Contineum Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Which has higher earnings and valuation, CTNM or TYRA? Contineum Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M2.06-$42.26M-$1.97-2.02Tyra BiosciencesN/AN/A-$86.48M-$1.63-6.13 Is CTNM or TYRA more profitable? Contineum Therapeutics' return on equity of -24.59% beat Tyra Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -24.59% -23.49% Tyra Biosciences N/A -26.90%-25.54% Do analysts recommend CTNM or TYRA? Contineum Therapeutics presently has a consensus target price of $22.50, suggesting a potential upside of 466.04%. Tyra Biosciences has a consensus target price of $30.83, suggesting a potential upside of 208.49%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Tyra Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in CTNM or TYRA? 84.1% of Tyra Biosciences shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by insiders. Comparatively, 15.2% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor CTNM or TYRA? In the previous week, Tyra Biosciences had 6 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Tyra Biosciences and 0 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.00 beat Tyra Biosciences' score of -0.08 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Contineum Therapeutics Neutral Tyra Biosciences Neutral SummaryContineum Therapeutics beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.49M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-2.0221.5627.4020.04Price / Sales2.06281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book0.527.518.085.67Net Income-$42.26M-$55.05M$3.16B$248.47M7 Day Performance-0.87%3.16%2.12%2.90%1 Month Performance-16.14%5.92%4.43%5.75%1 Year Performance-80.21%5.82%35.62%21.36% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.207 of 5 stars$3.98-0.6%$22.50+466.0%-80.7%$103.49M$50M-2.0231TYRATyra Biosciences1.8183 of 5 stars$9.71+5.2%$30.83+217.5%-39.8%$490.02MN/A-5.9620News CoverageAnalyst ForecastMAZEMaze TherapeuticsN/A$10.73-4.0%$25.67+139.2%N/A$489.65M$167.50M0.00121VALNValneva1.6367 of 5 stars$5.56-1.1%$15.50+178.8%-20.3%$478.23M$183.52M-4.67700SEPNSepterna1.7027 of 5 stars$10.53+0.6%$26.75+154.0%N/A$466.52M$977K0.00N/AATYRaTyr Pharma2.9919 of 5 stars$4.98-4.6%$20.20+305.6%N/A$464.60M$230K-6.1553News CoverageGap UpHigh Trading VolumeMREOMereo BioPharma Group1.9833 of 5 stars$2.74-3.9%$7.60+177.4%-16.8%$453.15M$10M-39.1440CGEMCullinan Therapeutics1.5362 of 5 stars$7.58-1.2%$30.00+295.8%-52.4%$452.65MN/A-2.6030Positive NewsGap UpAMLXAmylyx Pharmaceuticals3.619 of 5 stars$5.02-0.6%$10.14+102.0%+277.6%$450.16M$87.37M-1.61200ZYBTZhengye BiotechnologyN/A$7.43-20.1%N/AN/A$438.65MN/A0.00278News CoverageLockup ExpirationORKAOruka Therapeutics2.2137 of 5 stars$10.90-6.7%$40.38+270.4%N/A$437.30MN/A-2.42N/A Related Companies and Tools Related Companies TYRA Competitors MAZE Competitors VALN Competitors SEPN Competitors ATYR Competitors MREO Competitors CGEM Competitors AMLX Competitors ZYBT Competitors ORKA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts